There have been over 2,000 scientific papers showing that APC, an endogenous human protein, has potent anti-inflammatory, cytoprotective and regenerative properties. APC has been shown to be an effective therapeutic in numerous diseases - https://pubmed.ncbi.nlm.nih.gov/25824691/. Figure A below illustrates APC’s very effective mechanisms of action on Protease-activated Receptors PAR-1 and PAR-3.
Novapep’s scientists have invented peptide structures which mimic the cell signalling of APC. These peptide structures are significantly cheaper to manufacture than APC and are stable at room temperature, enabling them to be developed as therapeutic drugs. Figure B below illustrates the P1 (TR47) and P3 (3PR) agonist peptides which mimic APC’s anti-inflammatory mechanisms of action. Figure C below shows the linked form of P1 and P3 called biparetide, which generates synergistic cell-signalling effects significantly greater than P1 and P3 individually.
Novapep’s biparetide agonist peptide structure heralds a first in class, easy to use drug for the treatment of diseases where there are unmet medical needs.
The Griffin & Mosnier Labs have optimised biparetide, to be used for oral, topical and systemic administration in Novapep’s Inflammatory skin disorders and inflammatory bowel disease target indications. Novapep is undertaking further animal studies in its programs in 2024 and will start biparetide pre-clinical work leading to a Phase 1 clinical trial in late 2025.